Story detail view · 2026-07
STAT+: RA Capital backs upstart rival to Ultragenyx and Ionis in rare brain disease

STAT+: RA Capital backs upstart rival to Ultragenyx and Ionis in rare brain disease

Quick Summary

Oak Hill Bio, a new company backed by RA Capital and other investors, will take on Ultragenyx and Ionis in developing an Angelman syndrome medicine.

Continue Reading on STAT News

Get instant updates on Telegram

Join our channel to receive the latest headlines and breaking stories as soon as they are published.

Join channel

Comments (0)

Join the conversation. Comments are rate-limited, secured, and GDPR-compliant.

No comments yet. Be the first to share your thoughts!

Write a comment

0 / 500